Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

strative expenses. As of June 30, 2013, Orexigen had $55.8 million in cash and cash equivalents and an additional $40.2 million in marketable securities, for a total of $96.0 million.

Product candidates: Contrave (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double-blind, randomized, placebo-controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA (United States Food and Drug Administration), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis and NDA resubmission is planned once the independent Data Monitoring Committee (DMC) has determined that sufficient information has been gathered for the analysis that would include at least 87 adjudicated major adverse cardiovascular events (MACE). Orexigen enrolled into the Light Study a patient population that the company predicted would have an annualized MACE rate between 1% and 2%. Orexigen is preparing to be ready to conduct the interim analysis and resubmit the Contrave NDA in the remaining months of 2013. Orexigen has licensed North American commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights throughout the rest of the world and intends to license commercial rights outside North America.

Empatic™, a fixed dose combination of bupropion SR and zonisamide SR, for the treatment of obesity: In a series of discussions with the FDA on the continued development of Empatic, the FDA stated that Phase 3 data for Empatic may be sufficient to support submission of an NDA without data from a cardiovascular outcomes trial. The FDA indicated that as long as the placebo-subtracted changes in body weight, blood pressure
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , VENLO, Netherlands , Feb. 2 QIAGEN N.V. ... financial results call. The Webcast will take place at 9:30 a.m. EST on ... President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , ... QIAGEN,s fourth quarter and year-end 2009 financial , ...
... , JERUSALEM , Feb. ... ) announced today the availability of new resources to support ... to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand ... due to inadequate secretion of normal endogenous growth hormone. The ...
Cached Medicine Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6
(Date:10/1/2014)... This October, Request A Test , a leading ... 10% off all testing for Diabetes . Customers ... save. The Center for Disease Control (CDC) reports that ... Diabetes. Because many people do not display symptoms, it ... serious health problems. Blood testing can help a person ...
(Date:10/1/2014)... October 01, 2014 After a run ... "Beautiful Births", emerging filmmaker Jacqui Blue is continuing her ... discover the truth about natural birth. The documentary has ... over the world and has been an effective medium ... the topics highlighted in the film provide a wealth ...
(Date:10/1/2014)... 01, 2014 The Oliver Law ... new Other-Sonic Ultrasound Gel lawsuit web page ... the litigation surrounding the 2011 Pseudomonas aeruginosa / ... Royal Oak, Michigan, which was ultimately traced to ... representing William Beaumont patients who allegedly became ill ...
(Date:10/1/2014)... October 01, 2014 Indosoft, Inc., a leading ... announces that it has added support for Sangoma Lyra ... and Indosoft have a history of bringing innovative ... patent-pending technology offers a significant benefit to those using Asterisk ... is now available to users of Q-Suite. , In the ...
(Date:10/1/2014)... 01, 2014 The annual Social Security cost-of-living ... 2015, says a new forecast by The Senior Citizens ... price index (CPI) data through August, TSCL forecasts that COLAs ... the sixth consecutive year of record low COLAs,” states TSCL ... became automatic in 1975,” he notes. , Over the past ...
Breaking Medicine News(10 mins):Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... , TUESDAY, Jan. 24 (HealthDay News) -- People without ... medical care or prescription drugs than people with jobs who ... the depths of the recent recession, unemployment reached 9.6 percent, ... access to care and most people rely on getting insured ...
... , TUESDAY, Jan. 24 (HealthDay News) -- Children with ... gastroesophageal reflux don,t get additional asthma control from acid-reducing ... these medications when there are no digestive issues increases ... the study. "There,s a strong epidemiological link between ...
... , TUESDAY, Jan. 24 (HealthDay News) -- If you have ... of painful flare-ups, new research suggests. The new study ... in the previous four months. They were divided into three ... or skim milk powder enriched with glycomacropeptide (GMP) and G600 ...
... from Rhode Island Hospital reports on the impact to ... upcoming revision to the Diagnostic and Statistical Manual, 5th ... these changes could result in false-negative diagnoses for patients. ... Clinical Psychiatry and is now available online in ...
... announce that it has entered a new long-term collaboration with ... journal Alcohol and Alcoholism . At the end ... the journal Alcohol and Alcoholism , which was previously ... founded in 1967 to improve the understanding and management of ...
... German . Studies currently available provide ... be detected and treated earlier, and consequently tumours occur less ... In this context, an HPV test can be used alone ... both screening procedures also carry a risk of harm in ...
Cached Medicine News:Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 2Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 3Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 2Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 3Health News:Enriched Skim Milk Good for Gout, Study Suggests 2Health News:The impact of deleting 5 personality disorders in the new DSM-5 2Health News:Oxford University Press and Medical Council on Alcohol announce long-term partnership 2Health News:HPV testing: Indications of a benefit in primary screening 2Health News:HPV testing: Indications of a benefit in primary screening 3Health News:HPV testing: Indications of a benefit in primary screening 4
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and ... programs are designed to assist POLs, clinics ... are designed to assure accuracy of patient ... regulatory requirements. Participation provides the opportunity to ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: